Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by farmerjaneon Apr 24, 2015 5:56pm
211 Views
Post# 23662963

MyMyMy Another PP

MyMyMy Another PPHans Blacks buddies he recruited to this board are at it again......I don't think they are interested in doing any deals ? So much for exploring options ? This has probably been the game plan all along again. I am sure you will hear every excuse and reason why a deal does not happen but yet the science is top notch.

Mislead investors, withhold information, an outside investor from this planet or as far away as the  moon would not invest in this thing the way it has been financially engineered to insiders  and presented to the public.  The only reasonable scenario is Insiders taking up most of the  Private Placement what normal investor would ?

These characters have played people enough, time for each one of you to start emailing and contacting your Politicians and the Securities Commisson who keeps approving this. Maybe someone in the OSC is being bought off.  Time to expose these guys for what they really are, Cashman is part of this....
Bullboard Posts